Logo

Targovax ASA Entered into a Clinical Collaboration and Supply Agreement with Agenus TG Mutant KRAS Cancer Adjuvanted with QS-21 STIMULON

Share this

Targovax ASA Entered into a Clinical Collaboration and Supply Agreement with Agenus TG Mutant KRAS Cancer Adjuvanted with QS-21 STIMULON

Shots:

  • The companies collaborated to develop Targovax´s TG mutant KRAS cancer vaccines in combination with Agenus´ QS-21 STIMULON adjuvant technology
  • Agenus will be responsible to supply QS-21 STIMULON and providing scientific support for up to three initial TG01 clinical trials in different cancer indications. Additionally, QS-21 STIMULON demonstrated powerful Ab and cell-mediated immune responses along with a favorable safety profile
  • The collaboration may be extended into a development and commercialization agreement for KRAS vaccination if the combination proves effective in exploratory clinical studies where Agenus will be eligible to receive royalties on future TG vaccine sales

Ref: Targovax | Image: Targovax

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions